Recent studies suggest that the presence of medium-chain acyl-CoA dehydrogenase (ACADM) in exosomes derived from pancreatic cancer cells can be used as a marker for gemcitabine treatment sensitivity. The gene discussed is ACADM; the disease is pancreatic neoplasm.